New targeted agent produces considerable responses in patients with uterine cancer

(Dana-Farber Cancer Institute) The DNA repair-blocking drug adavosertib shrinks tumors in nearly one-third of patients in clinical trial data to be shared at the Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news